Sone Capital Management LLC Acquires Shares of 14,256 Zoetis Inc. (NYSE:ZTS)

Sone Capital Management LLC acquired a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 14,256 shares of the company’s stock, valued at approximately $2,323,000.

Other large investors have also recently made changes to their positions in the company. Mission Wealth Management LP increased its stake in Zoetis by 2.0% in the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company’s stock worth $479,000 after acquiring an additional 59 shares during the last quarter. VeraBank N.A. increased its position in Zoetis by 4.1% in the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock worth $254,000 after purchasing an additional 62 shares during the last quarter. HUB Investment Partners LLC raised its stake in Zoetis by 4.7% during the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company’s stock valued at $224,000 after purchasing an additional 62 shares in the last quarter. Procyon Advisors LLC lifted its position in Zoetis by 1.4% during the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock valued at $768,000 after purchasing an additional 63 shares during the last quarter. Finally, Coppell Advisory Solutions LLC lifted its position in Zoetis by 18.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company’s stock valued at $68,000 after purchasing an additional 64 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Insider Transactions at Zoetis

In other news, Director Willie M. Reed sold 1,210 shares of the firm’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the sale, the executive vice president now owns 15,781 shares of the company’s stock, valued at $2,682,770. The trade was a 2.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.18% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ZTS. Barclays upped their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Stifel Nicolaus decreased their price objective on Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a research report on Monday, April 14th. StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Morgan Stanley dropped their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Finally, Piper Sandler increased their price target on Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a report on Monday, May 12th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $212.75.

Zoetis Trading Up 1.7%

Shares of NYSE ZTS opened at $163.03 on Monday. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The company has a market cap of $72.58 billion, a price-to-earnings ratio of 29.80, a PEG ratio of 2.78 and a beta of 0.94. The business’s 50 day moving average price is $156.46 and its 200-day moving average price is $165.22.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The business had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business’s revenue was up 1.4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.38 earnings per share. On average, sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.